Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes

In a trial with 731 participants, mazdutide 4 mg and 6 mg showed superior reductions in HbA1c and body weight compared to dulaglutide 1.5 mg over 28 weeks.

• Both doses of mazdutide demonstrated non-inferiority and superiority to dulaglutide in mean change in HbA1c from baseline to week 28.
• The least squares mean treatment difference in HbA1c was -0.24% for mazdutide 4 mg and -0.30% for mazdutide 6 mg compared to dulaglutide.
• Mazdutide 4 mg and 6 mg achieved greater weight reductions, with a mean treatment difference of -3.78% and -5.76%, respectively, compared to dulaglutide.
• A higher percentage of participants receiving mazdutide reached the composite endpoint of HbA1c < 7.0% with ≥ 5% weight reduction compared to dulaglutide.
• Gastrointestinal adverse events, including diarrhoea, nausea, and vomiting, were the most common treatment-emergent adverse events.

AI simplified